Country: United States
Language: English
Source: NLM (National Library of Medicine)
LEVONORGESTREL (UNII: 5W7SIA7YZW) (LEVONORGESTREL - UNII:5W7SIA7YZW), ETHINYL ESTRADIOL (UNII: 423D2T571U) (ETHINYL ESTRADIOL - UNII:423D2T571U)
Teva Pharmaceuticals USA, Inc.
LEVONORGESTREL
LEVONORGESTREL 0.15 mg
PRESCRIPTION DRUG
CAMRESE® is indicated for use by females of reproductive potential to prevent pregnancy. CAMRESE is contraindicated in females who are known to have or develop the following conditions: - A high risk of arterial or venous thrombotic diseases. Examples include females who are known to: Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions (5.1)]. Have current or history of deep vein thrombosis or pulmonary embolism [see Warnings and Precautions (5.1 )]. Have cerebrovascular disease [see Warnings and Precautions (5.1 )] Have coronary artery disease [see Warnings and Precautions (5.1 )]. Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions (5.1 )]. Have inherited or acquired hypercoagulopathies [see Warnings and Precautions (5.1 )]. Have uncontrolled hypertension or hypertension with vascular disease [see Warnings and Precautions (5.3)]. Hav
How Supplied CAMRESE tablets (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets) are available in Extended-Cycle Tablet Dispensers (NDC 0093-3134-82), each containing a 13-week supply of tablets: 84 light blue-green tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg ethinyl estradiol, and 7 yellow tablets each containing 0.01 mg of ethinyl estradiol. The light blue-green tablets are round, film-coated, biconvex, unscored tablets debossed with stylized b on one side and 555 on the other side. The yellow tablets are round, biconvex, film-coated, unscored tablets debossed with stylized b on one side and 556 on the other side. Box of 2 Extended-Cycle Tablet Dispensers NDC 0093-3134-82 Storage and Handling Store at 20°C to 25°C (68°F to 77° F); excursions permitted to 15ºC to 30ºC (59ºF to 86ºF) [See USP Controlled Room Temperature].
New Drug Application Authorized Generic
CAMRESE- LEVONORGESTREL / ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL TEVA PHARMACEUTICALS USA, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE CAMRESE SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR CAMRESE. CAMRESE® (LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS; ETHINYL ESTRADIOL TABLETS) FOR ORAL USE INITIAL U.S. APPROVAL: 1982 WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ CAMRESE IS CONTRAINDICATED IN WOMEN OVER 35 YEARS OLD WHO SMOKE. CIGARETTE SMOKING INCREASES THE RISK OF SERIOUS CARDIOVASCULAR EVENTS FROM COMBINATION ORAL CONTRACEPTIVE (COC) USE. RECENT MAJOR CHANGES Contraindications, Pregnancy (4) Removed 01/2023 Warnings and Precautions, Malignant Neoplasms (5.11) 04/2022 INDICATIONS AND USAGE CAMRESE is a combination of levonorgestrel, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. (1) DOSAGE AND ADMINISTRATION Take one tablet daily by mouth at the same time every day for 91 days in the order directed on the blister pack. (2) DOSAGE FORMS AND STRENGTHS CAMRESE consists of 84 light blue-green tablets containing 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol, and 7 yellow tablets containing 0.01 mg ethinyl estradiol. (3) CONTRAINDICATIONS A high risk of arterial or venous thrombotic diseases (4) Undiagnosed abnormal uterine bleeding (4) Breast cancer (4) Liver tumors or liver disease, acute viral hepatitis or decompensated cirrhosis (4) Co-administration with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir.(4) WARNINGS AND PRECAUTIONS Vascular risks: Stop if a thrombotic or thromboembolic event occurs. Stop at least 4 weeks before and through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding. Consider cardiovascular risk factors before initiating in a Read the complete document